tiprankstipranks
Advertisement
Advertisement

FATE Stock Latest News

Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial
Company AnnouncementsFate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial
2d ago
FATE
Fate Therapeutics Advances FT819 Cell Therapy Into Phase 2 Lupus Nephritis Trial
PremiumCompany Announcements
Fate Therapeutics Advances FT819 Cell Therapy Into Phase 2 Lupus Nephritis Trial
2d ago
FATE
Analyst Maintains Hold on Fate Therapeutics as Off‑the‑Shelf CAR‑T Pipeline Advances but Key Efficacy Data Remain Early
PremiumRatings
Analyst Maintains Hold on Fate Therapeutics as Off‑the‑Shelf CAR‑T Pipeline Advances but Key Efficacy Data Remain Early
18d ago
FATE
Fate Therapeutics reports Q2 EPS (25c), consensus (26c)
PremiumThe Fly
Fate Therapeutics reports Q2 EPS (25c), consensus (26c)
18d ago
FATE
Fate Therapeutics price target raised to $3.50 from $2.50 at Wells Fargo
PremiumThe Fly
Fate Therapeutics price target raised to $3.50 from $2.50 at Wells Fargo
19d ago
FATE
Fate Therapeutics intiates first patient in RECLAIM-LN trial
PremiumThe FlyFate Therapeutics intiates first patient in RECLAIM-LN trial
19d ago
FATE
Fate Therapeutics price target raised to $8 from $6 at Piper Sandler
Premium
The Fly
Fate Therapeutics price target raised to $8 from $6 at Piper Sandler
19d ago
FATE
FATE Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
FATE Upcoming Earnings Report: What to Expect?
1M ago
FATE
Fate Therapeutics: FT839 Advancement and Autoimmune Potential Underpin Buy Rating, 12-Month $7 Price Target Reaffirmed
PremiumRatings
Fate Therapeutics: FT839 Advancement and Autoimmune Potential Underpin Buy Rating, 12-Month $7 Price Target Reaffirmed
2M ago
FATE
Fate Therapeutics announces FDA clearance of FT839 IND application
PremiumThe Fly
Fate Therapeutics announces FDA clearance of FT839 IND application
2M ago
FATE
Fate Therapeutics Shareholders Back Directors and Governance Plans
PremiumCompany Announcements
Fate Therapeutics Shareholders Back Directors and Governance Plans
3M ago
8K
FATE
Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline
PremiumCompany Announcements
Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline
3M ago
8K
FATE
Gil Blum Reiterates Hold on Fate Therapeutics as Early FT819 Data Show Promise but Uncertain Durability
PremiumRatingsGil Blum Reiterates Hold on Fate Therapeutics as Early FT819 Data Show Promise but Uncertain Durability
3M ago
FATE
Fate Therapeutics management to meet with Piper Sandler
Premium
The Fly
Fate Therapeutics management to meet with Piper Sandler
3M ago
FATE
5 Healthcare Stocks Set to Join the Russell 3000
Premium
Market News
5 Healthcare Stocks Set to Join the Russell 3000
3M ago
QSI
AGEN
CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts
PremiumWeekend Updates
CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts
3M ago
AMT
CTMX
Fate Therapeutics price target raised to $2.20 from $2 at BofA
PremiumThe Fly
Fate Therapeutics price target raised to $2.20 from $2 at BofA
4M ago
FATE
Fate Therapeutics assumed with a Buy at Jefferies
PremiumThe Fly
Fate Therapeutics assumed with a Buy at Jefferies
4M ago
FATE
Gil Blum Maintains Hold Rating Amid Uncertainty on FT819 Durability and Rising Competition in Lupus Nephritis Cell Therapies
PremiumRatings
Gil Blum Maintains Hold Rating Amid Uncertainty on FT819 Durability and Rising Competition in Lupus Nephritis Cell Therapies
4M ago
FATE
Tara Bancroft Reiterates Hold Rating as FT819’s Autoimmune Momentum Offsets Early-Stage, Regulatory and Execution Risks
PremiumRatingsTara Bancroft Reiterates Hold Rating as FT819’s Autoimmune Momentum Offsets Early-Stage, Regulatory and Execution Risks
4M ago
FATE
Fate Therapeutics reports Q1 EPS (26c), consensus (28c)
Premium
The Fly
Fate Therapeutics reports Q1 EPS (26c), consensus (28c)
4M ago
FATE
Fate Therapeutics price target raised to $7 from $5 at H.C. Wainwright
Premium
The Fly
Fate Therapeutics price target raised to $7 from $5 at H.C. Wainwright
4M ago
FATE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >